Semaglutide vs Tirzepatide
Semaglutide (Ozempic, Wegovy) vs tirzepatide (Mounjaro, Zepbound): head-to-head SURPASS-2 and SURMOUNT-5 results, weight loss, side effects and uses.
Inside Peptides comparative reviews analyze underlying receptor biology, molecular mechanisms, human clinical trial data, official regulatory statuses, and safety profiles, rather than asking “which one is better?”.
Identify the receptor, formulation, and biological context.
Compare the studied populations, outcomes, and limitations.
Check product-specific risks and regulatory scope.
Choose two compounds to check whether a published side-by-side review is available.
Browse 60 comparisons covering mechanisms, evidence, safety and regulatory context. Direct comparative trials are not available for every pair.
Showing all 60 comparisons
Semaglutide (Ozempic, Wegovy) vs tirzepatide (Mounjaro, Zepbound): head-to-head SURPASS-2 and SURMOUNT-5 results, weight loss, side effects and uses.
BPC-157 vs TB-500 for healing: what the small human reports and animal studies show, safety gaps, FDA compounding status and sport rules.
CJC-1295 vs ipamorelin: how each triggers growth hormone, what human studies found, side effects, FDA status and anti-doping rules. No dosing advice.
Semaglutide vs liraglutide: STEP 8 head-to-head weight results, weekly vs daily injections, side effects and approved uses compared.
Compare Tirzepatide and Liraglutide: mechanisms, human evidence, study limitations, safety considerations and regulatory context.
Compare Semaglutide and Exenatide: human vs exendin-4 architecture, SUSTAIN-3 clinical trial data, weekly vs twice-daily dosing, and safety.
Compare Liraglutide and Exenatide: LEAD-6 head-to-head clinical trial data, human peptide vs exendin-4 pharmacology, daily vs twice-daily dosing.
Compare Tirzepatide and Exenatide: dual GIP/GLP-1 co-agonism vs exendin-4 mono-agonism, clinical trial glycemic and weight endpoints, and safety.
Compare Semaglutide and native GLP-1: pharmaceutical engineering, DPP-4 enzymatic degradation, albumin binding, and clinical pharmacology.
Compare Tirzepatide and native GIP: twincretin pharmacology, GIP receptor internalization, biased signaling, and adipose tissue lipid buffering.
Understand GLP-1 versus GIP: where these gut hormones originate, insulin and glucagon effects, receptor signaling and the limits of drug comparisons.
Compare Semaglutide and Pramlintide: GLP-1 receptor vs amylin receptor agonism, mealtime vs weekly dosing, type 1 and type 2 diabetes indications.
Compare Insulin and Pramlintide: pancreatic beta-cell co-secretion, anabolic storage vs postprandial glucagon suppression, and type 1 diabetes management.
Compare GLP-1 and Peptide YY (PYY): L-cell co-secretion, GLP-1R vs Y2 receptor activation, gastric emptying, and appetite suppression.
Compare Insulin and Glucagon: anabolic storage vs catabolic mobilization, beta vs alpha cell physiology, rescue glucagon, and artificial pancreas systems.
Insulin vs semaglutide (Ozempic): how each lowers blood sugar, effects on weight, heart outcomes, side effects and when each is used.
Compare CJC-1295 and Tesamorelin: GHRH receptor agonism, covalent DAC albumin binding vs hexenoyl modification, trial history, and FDA approval.
Compare Tesamorelin and Ipamorelin: GHRH receptor agonist vs selective GHSR-1a ghrelin receptor secretagogue, FDA approval, and clinical evidence.
Compare Ipamorelin and native Ghrelin: GHSR-1a selectivity, octanoylation, growth hormone release vs orexigenic appetite surges, and ACTH/cortisol sparing.
Compare CJC-1295 and AOD-9604: systemic GHRH secretagogue elevation vs C-terminal hGH 177-191 lipolytic fragment, clinical trial failure, and safety.
Compare Tesamorelin and AOD-9604: FDA-approved visceral adiposity therapy vs failed lipolytic fragment, clinical trial data, and regulatory status.
BPC-157 vs GHK-Cu: a synthetic stomach-derived peptide vs a natural copper peptide used in skincare. Evidence, safety and regulatory status.
Compare TB-500 and GHK-Cu: actin-sequestering thymosin fragment vs copper tripeptide, cell motility vs collagen synthesis, and regulatory status.
Compare BPC-157 and KPV: synthetic gastric pentadecapeptide vs alpha-MSH tripeptide, VEGFR2/eNOS vs NF-kB inhibition, gut mucosal repair, and safety.
Compare KPV and GHK-Cu: two bioactive tripeptides evaluated across anti-inflammatory NF-kB inhibition, copper-dependent collagen remodeling, and wound healing.
Compare Semax and Selank: ACTH(4-10) vs Tuftsin analogues, Pro-Gly-Pro stabilization, BDNF elevation vs GABA-A allosteric modulation, and clinical indications.
Semax vs epitalon: a Russian-developed brain peptide vs an anti-ageing tetrapeptide. What human and animal studies show, safety and status.
Compare Selank and Epitalon: synthetic tuftsin anxiolytic vs pineal bioregulator tetrapeptide, GABA-A modulation vs circadian melatonin and telomerase.
Bremelanotide (Vyleesi), an FDA-approved treatment for low sexual desire, vs KPV, an experimental anti-inflammatory peptide. Evidence and safety.
Bremelanotide (Vyleesi) vs oxytocin: how each acts in the brain, approved uses, trial evidence and safety, compared side by side.
Octreotide (Sandostatin) vs lanreotide (Somatuline): somatostatin analogues for acromegaly and neuroendocrine tumours. PROMID vs CLARINET compared.
Teriparatide (Forteo) vs abaloparatide (Tymlos) for osteoporosis: fracture trial results, bone density, hypercalcaemia rates and side effects.
Oxytocin vs vasopressin: two closely related hormones with different receptors and medical uses. Structure, function and clinical evidence.
MOTS-c vs AOD-9604 for metabolism and fat loss: a mitochondrial peptide vs a growth-hormone fragment. What the evidence shows and safety.
Compare MOTS-c and BPC-157: mitochondrial AMPK activator vs gastric cytoprotective pentadecapeptide, metabolic flexibility vs microvascular tissue repair.
LL-37 vs KPV: a human antimicrobial peptide vs an anti-inflammatory tripeptide. Mechanisms, human evidence, safety and status compared.
LL-37 vs GHK-Cu for wound healing: an antimicrobial human peptide vs a copper peptide used in skincare. Trial evidence and safety compared.
GHRP-2 vs GHRP-6: two synthetic ghrelin-receptor peptides that release growth hormone. Human data, diagnostic use, FDA safety concerns and WADA status.
GHRP-6 vs ipamorelin: two ghrelin-receptor peptides compared on selectivity, human studies, failed trials, FDA compounding concerns and WADA status.
Hexarelin vs ipamorelin: a potent, less selective GH-releasing peptide and a more selective one. Human studies, tolerance, FDA status and WADA rules compared.
DSIP vs Selank: a disputed 1970s sleep peptide and a Russian anxiety peptide. Human trial quality, mechanisms, FDA compounding concerns and evidence gaps.
Dihexa vs Semax: an animal-only dementia compound with a retracted key paper and a Russian nasal peptide. Human data, FDA concerns and evidence gaps.
Melanotan II vs bremelanotide: a near-identical peptide pair. One is an unapproved tanning injectable, the other an FDA-approved HSDD medicine (Vyleesi).
Matrixyl (palmitoyl pentapeptide-4) vs Argireline (acetyl hexapeptide-8): proposed mechanisms, small often industry-run trials and their cosmetic status.
Argireline vs SNAP-8: SNAP-8 extends the Argireline sequence by two amino acids. Compare their small, often industry-linked studies and cosmetic status.
Matrixyl vs GHK-Cu: two skin-care peptides with lab-based collagen claims, small and often industry-funded human studies, and no FDA drug approval.
Sermorelin vs tesamorelin: both mimic GHRH. Geref approvals ended in 2008; tesamorelin (Egrifta) is FDA-approved for HIV-related belly fat.
Sermorelin vs CJC-1295: a former FDA-approved GHRH fragment and a long-acting analogue that never finished development. Mechanisms, evidence and risks.
Retatrutide (investigational triple agonist) vs tirzepatide (approved as Mounjaro and Zepbound): receptor targets, weight results and safety.
Retatrutide (investigational) vs semaglutide (Ozempic, Wegovy): receptors, phase 3 weight results, safety and the missing head-to-head trial.
Cagrilintide alone, semaglutide alone and their CagriSema combination: amylin vs GLP-1 biology, REDEFINE and phase 2 results, safety and approval status.
Cagrilintide (investigational weekly amylin analogue) vs pramlintide (Symlin, approved mealtime add-on to insulin): receptors, trials, safety and status.
Survodutide and mazdutide both target glucagon and GLP-1 receptors. Compare phase 3 weight results, liver data, safety and U.S. versus China approval status.
Survodutide (investigational glucagon/GLP-1 agonist) vs semaglutide (approved GLP-1 drug): mechanism, phase 3 weight data, a phase 2 direct comparison, safety.
Mazdutide (GLP-1/glucagon) vs tirzepatide (GIP/GLP-1): receptor targets, trial evidence, U.S. regulatory status and safety. No head-to-head trial exists.
Dulaglutide vs semaglutide: the SUSTAIN 7 head-to-head trial, cardiovascular outcomes trials, U.S. labels and shared GLP-1 safety warnings from primary sources.
Dulaglutide vs liraglutide: the AWARD-6 head-to-head trial, REWIND and LEADER outcomes, weekly vs daily injection, U.S. labels and shared GLP-1 warnings.
Lixisenatide vs exenatide: the GetGoal-X head-to-head trial, ELIXA and EXSCEL outcomes, current U.S. availability and the Parkinson's disease evidence.
Setmelanotide treats rare genetic and hypothalamic obesity via MC4R; semaglutide treats common obesity via GLP-1. Why they are not alternatives, with sources.
Melanotan II vs afamelanotide: an unapproved tanning peptide with serious case reports vs the FDA-approved Scenesse implant for erythropoietic protoporphyria.
Scientific comparisons are structured across regulatory classes and biological systems to evaluate compounds under relevant clinical and research standards.
Peer-reviewed comparative analysis of peptides with official marketing authorization from regulatory agencies (FDA, EMA).
Side-by-side reviews of multi-agonists, investigational peptides, and regulatory neuropeptides in human clinical stages.
Objective comparisons of compounds studied primarily in preclinical laboratory and animal models without human drug approval.
Molecules that converge on identical or complementary receptor cascades, comparing binding affinity and signaling bias.
Comparisons across distinct molecular classes evaluated within shared therapeutic domains such as metabolic health, bone density, or wound repair.
Inside Peptides comparisons do not declare “winners” or recommend specific treatments. Every comparison is grounded in sources such as FDA prescribing information, ClinicalTrials.gov registrations, and peer-reviewed randomized controlled trials.
Learn more about how we evaluate clinical claims in our Evidence Methodology or explore the Evidence Center.